Clinical trial NCT00747929: Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
Official title: A Double-Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800, or 1600 mg/Day of S-2367 Administered Orally Once Daily With a Reduced Calorie Diet in Obese Males and Females
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Obesity
Keywords: Obesity
Lead sponsor: Shionogi Inc.
Sponsor class: INDUSTRY
First posted: 2008-09-08
Enrollment: 724
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: 1. To evaluate the effect of S-2367 on body weight when administered following a 6-week placebo lead-in period and then a 54-week 800 kilocalorie deficit reduced calorie diet compared to placebo in healthy obese male and female subjects
2. To evaluate the safety and tolerability of S-2367 during 54 weeks of drug exposure
3. To evaluate the steady-state/trough pharmacokinetics of S-2367


Eligibility criteria: Inclusion Criteria:

* Males and females between 18 and 65 years of age and body mass index between 30.0 to 45.0 kg/m2, inclusive, and a weight that has not fluctuated by more than 3% for the last 3 months
* Medically stable for 3 months prior to Visit 1 and in otherwise good health, with no clinically significant findings from medical history, physical examination, 12-lead electrocardiograms (ECG), and vital signs
* Clinical laboratory evaluations (including clinical chemistry \[fasted at least 8 hours\], complete blood count, urinalysis, including creatine phosphokinase, amylase, lipase, lipid profile, insulin, Homeostatic Model Assessment of Insulin Sensitivity Index, hemoglobin A1c, thyroid stimulating hormone, free thyroxine, cortisol, iron, and ferritin) within the reference range for the test laboratory, unless deemed not clinically significant by the investigator
* Males will be sterile or agree to use an approved method of contraception. Some of the approved methods of contraception for males includes a surgically sterile (for at least 3 months prior to Visit 1) female sexual partner; a postmenopausal (for at least 1 year since last menstrual cycle) female sexual partner; a female sexual partner who uses (for at least previous 3 months prior to Visit 1 and during study) oral, implantable, transdermal, or injectable oral contraceptives; or use of the following double-barrier method: male condom with spermicide
* Females will be non-pregnant, non-lactating, and either postmenopausal for at least 1 year since last menstrual period, surgically sterile for at least 3 months prior to Visit 1, or agree to use an approved method of contraception. Some of the approved methods of contraception for females include a sterile (for at least 3 months prior to Visit 1) male sexual partner; use of oral, implantable, transdermal, or injectable oral contraceptives; or use of one of the following double-barrier methods: intrauterine device with spermicide, diaphragm with spermicide, cervical cap with spermicide, female condom with spermicide, or a male condom with spermicide by the male sexual partner
* Able to understand and willing to sign an informed consent form and comply with all study procedures

Exclusion Criteria:

* History or clinical manifestations of significant metabolic, hepatic, immunological (e.g., human immunodeficiency virus/ acquired immunodeficiency syndrome), renal, hematological, pulmonary, cardiovascular, gastrointestinal (GI), urological, neurological, or psychiatric disorders
* History or presence of an abnormal ECG, which in the investigator's opinion, is clinically significant
* History or evidence of a psychological disorder, other than stable or controlled anxiety or depression, including but not limited to the schizophrenias. Treatment with an antidepressant or anxiolytic drug(s) will be permitted if the dose and form has remained stable for at least the previous 3 months and the medication is not precluded/ excluded by this protocol because of potential effects on body weight and is not expected to change during the remainder of this clinical protocol
* History or evidence of an eating disorder with a compensatory behavior such as "purging bulimia nervosa" or "non-purging bulimia nervosa"
* History of obesity of endocrine origin
* History of type 1 or type 2 diabetes mellitus
* Clinically significant hypertension defined as blood pressure \> 160/90 mm Hg for either the systolic or diastolic values in either the untreated or treated state
* Clinically significant GI history or surgery. NOTE: Appendectomy and cholecystectomy will be allowed
* Gastric bypass surgery, stomach banding surgery, or any other surgical procedure(s) that attempt to promote/aid weight loss
* History of polycystic ovarian syndrome
* History of fenfluramine or dexfenfluramine or "fen-phen" administration with abnormal findings on echocardiograms at the time of "fen-phen" discontinuation
* History of participation in any weight loss program within 3 months prior to Visit 1
* History of body weight loss or gain greater than 3% within 3 months prior to Visit 1
* History of alcoholism or drug addiction/ substance abuse within 1 year prior to Visit 1
* History of any tobacco-containing or nicotine-containing product use (including cigarette, pipe, cigar, chewing, nicotine patch, or nicotine gum) within 1 year prior to Visit 1
* Participation in any other investigational study drug trial in which receipt of investigational study drug occurred within 3 months prior to Visit 1
* Previous use or participation in a study of S-2367 or any other neuropeptide Y5 agonist or antagonist
* Participation in any weight loss medication/product study in which receipt of weight loss medication/product occurred within 3 months prior to Visit 1
* Use of any prescription or non-prescription over-the-counter (OTC) medication/product or herbal/phytotherapeutic/plant-derived medications/products within 3 months prior to Visit 1 that is intended to induce weight loss, appetite suppression, weight control, or treat obesity, including, but not limited to, phentermine, sibutramine, orlistat, ephedra, rimonabant and other anorexogenics and/or stimulants, as well as topiramate
* Use of chronic medications/products within 3 months prior to Visit 1 or during the study that are known to cause weight gain. The list includes but is not limited to amitriptyline (Elavil), paroxetine (Paxil), setraline (Zoloft), and mirtazepine (Remeron)
* Use of any prescription or non-prescription OTC medications/products within 1 month prior to Visit 1, unless deemed acceptable by the investigator. Some examples of allowed medications are stable use (over the 3-month period prior to Visit 1) of the following will be allowed: hormone replacement therapy (e.g., for postmenopausal women); antihypertensive agents (e.g., for hypertensive subjects); statins (e.g., for hyperlilidaemia); thyroid replacement therapy (e.g., for thyroid subjects and provided thyroid replacement therapy has been stable for 3 months and no clinically significant changes in thyroid stimulating hormone and/or free thyroxine occur\[s\] during the study); oral, implantable, transdermal, or injectable contraceptive(s), etc. Anticholinergics (if used acutely), centrally acting antihistamines, and anti-inflammatories will be also allowed. Continued, stable, moderate use (over 3 month period prior to Visit 1) of vitamins and minerals is allowed and additional use of multivitamin-mineral supplements (non-herbal) may be allowed by the investigator (or designee) as part of the study diet program
* Donation of blood or blood products 3 months prior to Visit 1 or during the entire study
* Any acute or chronic condition that, in the opinion of the investigator, would limit the subject's ability to complete and/ or participate in this clinical study

Primary outcomes:
measure: The change in body weight over the 54-week active therapy phase of the study
timeFrame: 54 weeks
Secondary outcomes:
measure: Change in body composition: calculated body mass index, waist circumference, hip circumference, and calculated waist-to-hip ratio
timeFrame: 54 weeks
measure: Steady-state/trough pharmacokinetic analysis
timeFrame: After 3, 12, 24, 36, and 54 weeks
measure: Safety and tolerability of S-2367
timeFrame: 54 weeks
Other outcomes:
Locations:
city: Mobile
country: United States
state: Alabama
city: Tucson
country: United States
state: Arizona
city: Hot Springs
country: United States
state: Arkansas
city: Carmichael
country: United States
state: California
city: Roseville
country: United States
state: California
city: Sacramento
country: United States
state: California
city: Stamford
country: United States
state: Connecticut
city: Coral Gables
country: United States
state: Florida
city: Jacksonville
country: United States
state: Florida
city: Stuart
country: United States
state: Florida
city: Atlanta
country: United States
state: Georgia
city: Chicago
country: United States
state: Illinois
city: Springfield
country: United States
state: Illinois
city: Evansville
country: United States
state: Indiana
city: Shawnee Mission
country: United States
state: Kansas
city: Milford
country: United States
state: Massachusetts
city: Gulfport
country: United States
state: Mississippi
city: Saint Louis
country: United States
state: Missouri
city: Omaha
country: United States
state: Nebraska
city: Berlin
country: United States
state: New Jersey
city: Manlius
country: United States
state: New York
city: Rochester
country: United States
state: New York
city: Concord
country: United States
state: North Carolina
city: Raleigh
country: United States
state: North Carolina
city: Salisbury
country: United States
state: North Carolina
city: Cleveland
country: United States
state: Ohio
city: Mogadore
country: United States
state: Ohio
city: Cranston
country: United States
state: Rhode Island
city: Greenville
country: United States
state: South Carolina
city: Bristol
country: United States
state: Tennessee
city: Burns
country: United States
state: Tennessee
city: Knoxville
country: United States
state: Tennessee
city: Houston
country: United States
state: Texas
city: Jackson
country: United States
state: Texas
city: San Antonio
country: United States
state: Texas
city: Richmond
country: United States
state: Virginia
city: Renton
country: United States
state: Washington
city: Green Bay
country: United States
state: Wisconsin
Study officials:
affiliation: Shionogi
name: Shionogi Clinical Trials Administrator Clinical Support Help Line
role: STUDY_DIRECTOR
References: